Blog

Originally thought to be a specific JAK1/3 inhibitor, it’s pleiotropic targeting in clinical trials makes it a pan-JAK inhibitor.Although Tofacitinib does not directly target TNF, IL17 & IL1 (3 pivotal…

2016 BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids The prescribing of many drugs in pregnancy is…

Scientists Speculate On What Caused The Bial Drug Testing Tragedy In France A round-up of the weekend's scientific speculation on whether off-target effects, drug… forbes.com|By David Kroll Amongst the postulates,…

CDC Reports Increasing Narcotic Deaths A recent Morbidity Mortality Weekly Report from the CDC reviewed the epidemic of drug overdose (poisoning) deaths in the USA. Since 2000, the rate of…

What is it? Osteoarthritis (OA), or degenerative joint disease, is the most common form of arthritis. It most often affects middle-aged and older people, involving the neck, lower back, knees,…

Ask the Expert: Arthritis and the Weather With winter soon approaching, people with arthritis often think about how the seasons and daily weather affect their pain and function. Studies have…

Bone Bruising and Bone Marrow Edema Syndromes Bone Bruising and Bone Marrow Edema Syndromes: Incidental Radiological Findings or Harbingers of…www.isakos.com Primary bone marrow oedema syndromes MRI scanning in patients with…

10 Ways Rheumatoid Arthritis Could’ve Killed Glenn Frey I was truly stunned Monday when it was announced… rheumnow.com With regards to arthritis, many assume that you should be stoic and…

Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis NEW YORK (Reuters Health)—Rituximab may calm juvenile idiopathic arthritis (JIA)-associated uveitis and especially benefit patients who haven’t responded to… www.the-rheumatologist.org Adalimumab effective…

ACR: First U.S. clinical practice guidelines arise for Sjögren’s syndrome management SAN FRANCISCO – Rituximab is, for now, the first-line option for Sjögren’s syndrome patients with systemic symptoms severe enough…